ADHD Biomarker Program
Attention Deficit Hyperactivity Disorder
Pre-clinicalActive
Key Facts
Indication
Attention Deficit Hyperactivity Disorder
Phase
Pre-clinical
Status
Active
Company
About Linus Biotechnology
LinusBio is a New York-based platform diagnostics company founded in 2019, focused on the novel field of temporal exposomics. Its core technology analyzes hair to reveal longitudinal molecular data, functioning as a biological recorder of environmental exposures and physiological changes. The company has achieved significant validation with FDA Breakthrough Device designation for its lead autism diagnostic biomarker and has launched its first commercial test, ClearStrand-ASD. LinusBio is leveraging its platform to build a pipeline targeting other complex CNS and systemic disorders.
View full company profileTherapeutic Areas
Other Attention Deficit Hyperactivity Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| ADHD Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| ADHD Stimulant APIs | Noramco | Commercial |
| ADHD Drug (unspecified) | Granules India | ANDA Tentative Approval |